Assessing the Quality of Life Using the Health Utilities Index Questionnaire in Children With Severe Persistent Asthma During the Treatment With Omalizumab

Background. Quality of life (QoL) is an important parameter that provides additional information about changes in health status. Objective. Our aim was to study the change in QoL of patients with severe persistent bronchial asthma (BA) during the treatment with genetically engineered biological preparation (GIBP) omalizumab in addition to daily background therapy. Methods. The QoL assessment was conducted using the Health Utilities Index Mark 3 and Mark 2 (HUI3, HUI2) questionnaires at two points (1st point and 2nd point — in 6 months) in 47 children with severe BA at the age of 13 (7; 17) years, 72% of them are boys. At the same points, QoL was evaluated using the PAQLQ (S) specialized pediatric questionnaire (Standardized Pediatric Asthma Quality of Life Questionnaire). Results. Depending on the duration of omalizumab therapy, all children were divided into 5 groups: 1st group — children who did not receive treatment with monoclonal antibodies at the 1st point; in 2, 3, 4, 5-th groups, the QoL assessment was performed on GIBP treatment for different time. In children of the 1st group whose QoL was evaluated before starting GIBP therapy and in 6 months, a statistically significant change in scores on the Health Utilities Index questionnaire was noted: the multi-attribute indices HUI2 and HUI3 improved, respectively, by 21.3 and 10.71% (p = 0.041 and 0.086). According to the HUI2 classification system, a significant improvement in the emotion attribute was revealed, which positively correlated with the overall indicator and the emotion indicator of the PAQLQ (S) questionnaire. In the remaining groups, the indicators of the Health Utilities Index questionnaire did not change significantly. Conclusion. The study results showed that the dynamics of the quality of life in children with severe persistent BA is an important additional criterion in a comprehensive assessment of the efficacy of targeted bioengineering therapy.

1. Баранов А.А., Альбицкий В.Ю., Винярская И.В. Изучение качества жизни в педиатрии. Серия: Социальная педиатрия. Вып. 10. — М.: Союз педиатров России; 2010. — 380 c. [Baranov AA, Al’bitskii VYu, Vinyarskaya IV. Izuchenie kachestva zhizni v pediatrii. Seriya: Sotsial’naya pediatriya. Issue. 10. Moscow: Soyuz pediatrov Rossii; 2010. 380 p. (In Russ).]

2. Post MW. Definitions of quality of life: what has happened and how to move on. Top Spinal Cord Inj Rehabil. 2014;20(3):167–180. doi: 10.1310/sci2003-167.

3. Wilson SR, Rand CS, Cabana MD, et al. Asthma outcomes: quality of life. J Allergy Clin Immunol. 2012;129(3 Suppl):S88–123. doi: 10.1016/j.jaci.2011.12.988.

4. van den Bemt L, Kooijman S, Linssen V, et al. How does asthma influence the daily life of children? Results of focus group interviews. Health Qual Life Outcomes. 2010;8:5. doi: 10.1186/1477-7525-8-5.

5. Эфендиева К.Е. Влияние различных методов лечения на качество жизни детей, страдающих бронхиальной астмой: Дис. … канд. мед. наук. — М.; 2005. 124 с. [Efendieva KE. Vliyanie razlichnykh metodov lecheniya na kachestvo zhizni detei, stradayushchikh bronkhial’noi astmoi. [dissertation] Moscow; 2005. 124 p. (In Russ).] Доступно по: http://medical-diss.com/ medicina/vliyanie-razlichnyh-metodov-lecheniya-na-kachestvozhizni-detey-stradayuschih-bronhialnoy-astmoy. Ссылка активна на 12.10.2017.

6. Аллергия у детей: от теории — к практике. Серия: Современная педиатрия: от теории — к практике / Под ред. Л.С. Намазовой-Барановой. — М.; 2011. — 668 с. [Allergiya u detei: ot teorii — k praktike. Seriya: Sovremennaya pediatriya: ot teorii — k praktike. Ed by L.S. Namazova-Baranova. Moscow; 2011. 668 p. (In Russ).]

7. globalasthmareport.org [Internet]. The global asthma report 2014 [cited 2017 Oct 19]. Available from: http://www.globalasthmareport.org/burden/burden.php.

8. Федеральные клинические рекомендации по оказанию медицинской помощи детям с бронхиальной астмой. — М.; 2016. — 33 с. [Federal’nye klinicheskie rekomendatsii po okazaniyu meditsinskoi pomoshchi detyam s bronkhial’noi astmoi. Moscow; 2016. 33 p. (In Russ).]

9. ginasthma.org [Internet]. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, revised 2017 [cited 2017 Oct 19]. Available from: www.ginasthma.org.

10. Государственный реестр лекарственных средств. [Gosudarstvennyi reestr lekarstvennykh sredstv. (In Russ).] Доступно по: http://grls.rosminzdrav.ru/Grls_ View_v2.aspx?routingGuid=52c5f6b2-a88d-44f5-b254-b55843df3502&t . Ссылка активна на 03.09.2017.

11. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–128. doi: 10.1097/00005650-200202000-00006.

12. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics. 1995;7(6):503–520. doi: 10.2165/00019053-199507060-00005.

13. qoltech.co.uk [Internet]. PAQLQ(S) - Standardised Paediatric Asthma Quality Of Life Questionnaire. [cited 2017 Sep 9]. Available from: https://www.qoltech.co.uk/paqlq_s.html.

14. Винярская И.В., Черников В.В., Терлецкая Р.Н., и др. Валидация русской версии опросника для оценки утилитарных индексов в педиатрической практике. Этап II // Вопросы современной педиатрии. — 2014. — Т.13. — №4 — С. 20–25. [Vinyarskaya IV, Chernikov VV, Terletskaya RN, et al. Validation of the Russian version of a questionnaire for the assessment of utilitarian indices in pediatric practice. Stage II. Current pediatrics. 2014;13(4):20–25. (In Russ).] doi: 10.15690/vsp.v13i4.1080.

15. Баранов А.А., Альбицкий В.Ю., Винярская И.В., и др. Создание и валидация русской версии опросника для оценки утилитарных индексов в педиатрической практике // Педиатрическая фармакология. — 2012. — Т.9. — №1 — С. 6–8. [Baranov AA, Albitskiy VYu, Vinyarskaya IV, et al. Development and validation of the Russian version of the questionnaire for the utilitarian indexes evaluation in pediatrician practice. Pediatric pharmacology. 2012;9(1):6–8. (In Russ).] doi: 10.15690/pf.v9i1.156.

16. Niven RM, Saralaya D, Chaudhuri R, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016;6(8):e011857. doi: 10.1136/bmjopen-2016-011857.

17. Куличенко Т.В., Намазова-Баранова Л.С., Торшхоева Р.М., и др. Анти-IgE-терапия тяжелой бронхиальной астмы у детей: двухлетний опыт // Педиатрическая фармакология. — 2010. — Т.7. — №3 — С. 57–65. [Kulichenko TV, Namazova-Baranova LS, Torshkhoeva RM, et al. Anti-IgE therapy for severe asthma in children: two-year trial. Pediatric pharmacology. 2010;7(3):57–65. (In Russ).]

18. Ungar WJ, Boydell K, Dell S, et al. A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma. Pharmacoeconomics. 2012;30(8):697– 712. doi: 10.2165/11597890-000000000-00000.

19. Knapp C, Madden V, Revicki D, et al. Health status and health-related quality of life in a pediatric palliative care program. J Palliat Med. 2012;15(7):790-797. doi: 10.1089/jpm.2011.0504.

20. Trevino RP, Pham TH, Edelstein SL. Obesity and preference-weighted quality of life of ethnically diverse middle school children: the HEALTHY study. J Obes. 2013;2013:206074. doi: 10.1155/2013/206074.

21. Nayiager T, Anderson L, Cranston A, et al. Health-related quality of life in long-term survivors of acute lymphoblastic leukemia in childhood and adolescence. Qual Life Res. 2017;26(5):1371-1377. doi: 10.1007/s11136-016-1462-8.